Featured Research

from universities, journals, and other organizations

Monoclonal antibody effective against norovirus

Date:
July 24, 2013
Source:
American Society for Microbiology
Summary:
Researchers have provided the first proof of concept data showing that a monoclonal antibody can neutralize human norovirus. This research could one day lead to effective therapies against the virus.

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) provide the first proof of concept data showing that a monoclonal antibody can neutralize human norovirus. This research, which could one day lead to effective therapies against the virus, was published online ahead of print in the Journal of Virology.

"We initiated this work because there is presently no virus-specific treatment or vaccine to control the norovirus illness," says Kim Y. Green, a researcher on the study. "Our working hypothesis was that a highly specific norovirus antibody that binds to the outer surface of the virus particle might prevent the ability of the virus to infect susceptible host cells."

The team first isolated genes from chimpanzee immune cells encoding norovirus-specific antibodies. They then converted these into human-compatible full-length immunoglobulin molecules. They successfully tested two of the antibodies against norovirus infection in chimpanzees.

"An effective therapeutic antibody might be explored as both a treatment for norovirus gastroenteritis, and as a disease prevention strategy," says Green. "Consider a developing outbreak scenario in which food-handlers, healthcare workers, deployed military, or travelers could reduce risk of infection, incapacitation, and spread if a safe and inexpensive treatment is immediately available."

Norovirus causes roughly 20 million cases of acute diarrhea and vomiting annually in the US, alone, according to the US Centers for Disease Control and Prevention (CDC). While in most people, symptoms last a day or two, for those with impaired immune systems, and the young and the aged, norovirus can be life-threatening. It is responsible for an estimated 70,000 hospitalizations and 800 deaths annually, and roughly one in 15 Americans get the disease every year. It is unusually contagious, via the fecal-oral route. People who have had norovirus remain highly contagious for at least three days after symptoms abate.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Z. Chen, S. V. Sosnovtsev, K. Bok, G. I. Parra, M. Makiya, L. Agulto, K. Y. Green, R. H. Purcell. Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis. Journal of Virology, 2013; DOI: 10.1128/JVI.01376-13

Cite This Page:

American Society for Microbiology. "Monoclonal antibody effective against norovirus." ScienceDaily. ScienceDaily, 24 July 2013. <www.sciencedaily.com/releases/2013/07/130724200623.htm>.
American Society for Microbiology. (2013, July 24). Monoclonal antibody effective against norovirus. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2013/07/130724200623.htm
American Society for Microbiology. "Monoclonal antibody effective against norovirus." ScienceDaily. www.sciencedaily.com/releases/2013/07/130724200623.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins